Skip to main content
Premium Trial:

Request an Annual Quote

Agilent, OGT Expand Array, Target Enrichment Partnership in New Deal


By Justin Petrone

Agilent Technologies will provide Oxford Gene Technology with oligonucleotide microarrays and SureSelect target enrichment products for use in OGT's next-generation sequencing services, the companies said this week.

The new agreement expands on an earlier pact inked in 2007, in which Agilent agreed to manufacture OGT-designed arrays for the British firm's customers, and OGT became an Agilent-certified service provider for the Santa Clara, Calif.-based life science tools vendor's microarrays. OGT was later certified as a high-throughput services provider, the only such firm to receive such a designation to date (BAN 3/2/2010).

According to OGT CEO Mike Evans, the deal with Agilent is exclusive in that OGT is compelled to offer Agilent arrays or SureSelect target enrichment products "unless the customer's specific requirements cannot be met with the existing Agilent product range."

In a statement, Evans characterized the pact as a "long-term agreement" that "enables OGT to offer its customers Agilent's ... product range at competitive prices within its ... microarray and sequencing services."

OGT introduced its sequencing services offering, called Genefficiency, earlier this year (BAN 5/13/2011). The company offers a menu of arrays for cytogeneticists called CytoSure, all of which are manufactured by Agilent. In addition to DNA arrays, OGT also maintains an internal protein array program that it gained through its acquisition of Sense Proteomic in 2008 (BAN 3/17/2009).

Further terms of the recent agreement were not available.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.